The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
Phones:
+7 (495) 482-4118
+7 (495) 482-4329
  • Toll-free number for subscriptions:
    +8 800 250-18-12
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Putilina M.V.

Pirogov Russian National Research Medical University

Shabalina N.I.

Central Clinical Hospital «RZD-Medicine»

Results of a pilot study of the structure and evaluation of the therapy for chronic sleep disorders in comorbid patients with chronic cerebral ischemia

Authors:

Putilina M.V., Shabalina N.I.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(4): 118‑126

DOI: 10.17116/jnevro2024124041118

Read: 3224 times

Contact the author
Table of contents

RESULTS OF A PILOT STUDY OF THE STRUCTURE AND EVALUATION OF THE THERAPY FOR CHRONIC SLEEP DISORDERS IN COMORBID PATIENTS WITH CHRONIC CEREBRAL ISCHEMIA
RESULTS OF A PILOT STUDY OF THE STRUCTURE AND EVALUATION OF THE THERAPY FOR CHRONIC SLEEP DISORDERS IN COMORBID PATIENTS WITH CHRONIC CEREBRAL ISCHEMIA

To cite this article:

Putilina MV, Shabalina NI. Results of a pilot study of the structure and evaluation of the therapy for chronic sleep disorders in comorbid patients with chronic cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(4):118‑126. (In Russ.)
https://doi.org/10.17116/jnevro2024124041118

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Psycho-emotional state and self-reported sleep quality in students with bimo­dality of the ability to be active in the morning and evening in the sleep—wake cycle. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):130-134
Targets of rational neuroprotection in the therapy of chro­nic cere­bral ischemia and the possibilities of achieving them. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):96-101
Sleep diso­rders after COVID-19 in patients with primary headaches. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):127-132
Sleep disturbances in patients with post-traumatic stress diso­rder: possible mechanisms and main treatment approaches. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):21-27
Asso­ciation of adipokines and sleep diso­rders among the 25—44 year-old people. Russian Journal of Preventive Medi­cine. 2025;(8):41-47
Analysis of the upper respiratory tracts of pate­nts with idiopathic condyle reso­rption. Russian Journal of Stomatology. 2025;(3):34-40
The place of physiotherapy in non-pharmacological treatment of inso­mnia: modern concepts. (Literature review). Problems of Balneology, Physiotherapy and Exercise Therapy. 2025;(4):36-46
Esta­blishing the dyna­mics of acti­vity and stability of total PSA samples in semen samples on gauze, dilu­ted with distilled water. Fore­nsic Medi­cal Expe­rtise. 2025;(5):39-42
Sleep diso­rders and leading chro­nic non-communicable diseases risk factors in loco­motive crew workers. Russian Journal of Preventive Medi­cine. 2025;(10):41-47
Comparison of pH in teeth bleaching systems. Stomatology. 2025;(5):12-17
Abstract:

OBJECTIVE

To evaluate the effect of the drug Cortexin on the clinical course and treatment of comorbid insomnia.

MATERIAL AND METHODS

The study included 50 patients, average age 50.4±2.26 years, with CHI stage 1—2. with concomitant diseases arterial hypertension, atherosclerosis, diabetes mellitus (study CHRONAS). All patients were examined on the day of treatment, 11—15 days and 30—31 days after the end of therapy. At all visits, complaints, neurological status, and changes in physiological and laboratory parameters were assessed. The condition was assessed using the following scales: mental status assessment (MMSE), quality of life questionnaire (EQ-5D), assessment of general health, Pittsburgh Sleep Quality Index (PSQI), Epworth daytime sleepiness assessment, hospital anxiety and depression (HADS)).: Patients with additional diabetic polyneuropathy were assessed using the Central Sensitization Inventory (CSI).

RESULTS

A high percentage of the prevalence of comorbid insomnia in patients was revealed. The structure of sleep disturbances in patients with chronic cerebral ischemia consisted of disturbances in sleep duration, difficulty falling asleep, frequent awakenings at night, and daytime sleepiness. After treatment, there was a regression of the main complaints, the severity of symptoms, including anxiety and depression, decreased, and a significant stabilization of cognitive status was observed. The positive dynamics persisted 1 month after the end of therapy. An additional normalizing effect of the drug on a number of biochemical parameters was revealed. Clinical dynamics were recorded already by the 11—15th day of treatment and persisted for up to 1 month. During observation, no patient had adverse drug interactions with other drugs (hypotensives, antiplatelet agents, statins).

CONCLUSIONS

The clinical effectiveness of the drug Cortexin has been proven for all types of sleep disorders. The clinical effectiveness of the drug Cortexin at a dose of 10 mg IM for 10 days has been proven in patients with chronic sleep disorders due to CHI.

Keywords:

sleep disorders
comorbid insomnia
chronic cerebral ischemia
daytime sleepiness
concentration
anxiety and depressive disorders
Cortexi
study CHRONAS

Authors:

Putilina M.V.

Pirogov Russian National Research Medical University

Shabalina N.I.

Central Clinical Hospital «RZD-Medicine»

Received:

16.01.2024

Accepted:

21.02.2024

Close metadata

References:

  1. Chattu VK, Manzar MD, Kumary S, et al. The Global Problem of Insufficient Sleep and Its Serious Public Health Implications. Healthcare (Basel). 2018;7(1):1.  https://doi.org/10.3390/healthcare7010001
  2. Stickley A, Leinsalu M, DeWilder JE, et al. Sleep problems and depression among 237,023 community adults in 46 low- and middle-income countries. Sci Rep. 2019;9(1):12011. https://doi.org/10.1038/s41598-019-48334-7
  3. Vancampfort D, Koyanagi A, Ward PB, et al. Perceived Stress and Its Relationship With Chronic Medical Conditions and Multimorbidity Among 229,293 Community-Dwelling Adults in 44 Low- and Middle-Income Countries. Am J Epidemiol. 2017;186(8):979-989.  https://doi.org/10.1093/aje/kwx159
  4. Putilina MV, Baranova OA. Results of the multicenter clinical and epidemiological observational program «GLOBUS» (determination of the prevalence of dizziness and assessment of therapy regimens at the outpatient level). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2014;114(5):33-38. (In Russ.).
  5. Screever EM, van der Wal MHL, van Veldhuisen DJ, et al. Comorbidities complicating heart failure: changes over the last 15 years. Clin Res Cardiol. 2023;112(1):123-133.  https://doi.org/10.1007/s00392-022-02076-1
  6. Pepin JL, Martinez-Garcia MA. Sleep disorders and cerebrovascular disease: the long and winding road. Eur Respir J. 2020;55(4):1901977. https://doi.org/10.1183/13993003.
  7. Qiao H, Peng Z, Li G, et al. The association between insomnia symptoms and risk of cardio-cerebral vascular events: A meta-analysis of prospective cohort studies. Eur J Prev Cardiol. 2017;24(10):1071-1082. https://doi.org/10.1177/2047487317702043
  8. Putilina MV. The role of arterial hypertension in the development of chronic cerebrovascular accident. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2014;114(9):124-128. (In Russ.).
  9. Mayer G, Happe S, Evers S, et al. Insomnia in neurological diseases. Neurol Res Pract. 2021;3(1):15.  https://doi.org/10.1186/s42466-021-00106-3
  10. Sweetman A, Lack L, Crawford M, Wallace DM. Comorbid Insomnia and Sleep Apnea: Assessment and Management Approaches. Sleep Med Clin. 2022;17(4):597-617.  https://doi.org/10.1016/j.jsmc.2022.07.006
  11. Pizova NV, Pizov AV, Soloviev IN. Insomnia: risk factors, gender and age characteristics and approaches to treatment. Medical Advice. 2022;16(11):62-70. (In Russ.). https://doi.org/10.21518/2079-701X-2022-16-11-62-70
  12. Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017;26(6):675-700.  https://doi.org/10.1111/jsr.12594
  13. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540-545.  https://doi.org/10.1093/sleep/14.6.540
  14. Central Sensitivity Syndromes, CSI. https://painrussia.ru/publications/the-questionnaires-and-scales-to-assess-pain/csi.default.ivp.php
  15. International classification of diseases 11 revision of ICD10. https://classinform.ru/mkb-10.htmlInternationalclassificationofdiseases10/
  16. Poluektov MG, Tsenteradze SL. The impact of sleep disorders on the occurrence and course of cerebral stroke. Meditsinskiy sovet = Medical Council. 2015;(2):10-15. (In Russ.).
  17. Liu X, Zhang J, Wang Y, et al. The Relationship between Sleep Duration and Stroke Risk: The Mediating Role of Physical Activity. Brain Sci. 2022;12(5):601.  https://doi.org/10.3390/brainsci12050601
  18. Putilina MV. Pathogenetic approaches to the treatment of sleep disorders in comorbid patients. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2022;122(11):11-16. (In Russ.). https://doi.org/10.17116/jnevro202212211111
  19. Gabelle A, Gutierrez L-A, Jaussent I, et al. On behalf of the MAPT/DSA Study Group. Excessive Sleepiness and Longer Nighttime in Bed Increase the Risk of Cognitive Decline in Frail Elderly Subjects: The MAPT-Sleep Study. front. Aging Neurosci. 2017;9:312.  https://doi.org/10.3389/fnagi.2017.00312
  20. Fedin AI, Bel’skaia GN, Kurushina OV, et al. Dose-dependent effects of cortexin in chronic cerebral ischemia (results of a multicenter randomized controlled study). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2018;118(9):35-42. (In Russ.). https://doi.org/10.17116/jnevro201811809135
  21. Yakovlev AA, Gulyaeva NV. Molecular partners of cortexin in the brain. Neurochemistry. 2017;33:1:91-96. (In Russ.). https://doi.org/10.1134/S1819712416040164
  22. Khavinson VKh. Medicinal peptide preparations: past, present, future. Clinical Medicine. 2020;98(3):165-177. (In Russ.). https://doi.org/10.30629/0023-2149-2020-98-3-165-177
  23. Karantysh GV, Abramchuk VA, Ryzhak GA, Mendzheritsky AM. Peptide regulation of behavior and mediator balance in old rats under conditions of carotid artery occlusion. Fundamental Research. 2013;(6)6:1406-1410. (In Russ.).
  24. Tsygan VN. Memory, attention, sleep and Cortexin (correction of disorders of the integrative functions of the brain). Cortexin — a five-year experience of domestic neurology. St. Petersburg, Science. 2005;136-145. (In Russ.).
  25. Gomazkov OA. Cortexin. Molecular mechanisms and targets of neuroprotective activity. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2015;115(8):99-104. (In Russ.). https://doi.org/10.17116/jnevro20151158199-104
  26. Putilina MV. Neuroplasticity as a basis for early rehabilitation of patients after a stroke. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2011;111(12-2):64-69. (In Russ.).
  27. Zhang J, Zhou Y. 14-3-3 Proteins in Glutamatergic Synapses. Hindawi Neural Plasticity. 2018;2018:8407609. https://doi.org/10.1155/2018/8407609
  28. Tanaka M, Vécsei L. Editorial of Special Issue ‘Dissecting Neurological and Neuropsychiatric Diseases: Neurodegeneration and Neuroprotection’. Int J Mol Sci. 2022;23:6991. https://doi.org/10.3390/ijms23136991
  29. Putilina MV, Mutovina ZYu, Kurushina OV, et al. Determination of the prevalence of postcovid syndrome and assessment of the effectiveness of the drug Cortexin in the treatment of neurological disorders in patients with postcovid syndrome. Results of the multicenter clinical and epidemiological observational program CORTEX2022;122(1):84-90. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2022;122(1):84-90. (In Russ.). https://doi.org/10.17116/jnevro202212201184
  30. Irwin MR. Sleep and inflammation: partners in sickness and in health. Nature Reviews Immunology, 2019;19(11):702-715. 
  31. Soudy R, Kimura R, Patel A. Short amylin receptor antagonist peptides improve memory deficits in Alzheimer’s disease mouse model. Sci Rep. 2019;9(1):10942. https://doi.org/10.1038/s41598-019-47255-9
  32. Chernykh AI, Komleva YK, Gorina YV, et al. Pro-inflammatory phenotype of perivascular astroglia and CD133+ progenitor cells of endotheliocytes in murine model of Alzheimer’s disease Fundamental and Clinical Medicine. 2018;3(1):6-15. (In Russ.). https://doi.org/10.23946/2500-0764-2018-3-1-6-15
  33. Report on the ligand-receptor interaction of Cortexin in a radioligand binding model, panel Eurofins Pharma Discovery Services, 2019. (In Russ.).
  34. Zhou X, Smith QR, Liu X. Brain-penetrating peptides and peptide-drug conjugates for overcoming the blood-brain barrier and combating diseases of the central nervous system. WIRES Nanomed Nanobiotechnol. 2021;13(4):e1695. https://doi.org/10.1002/wnan.1695
  35. Putilina MV. The use of neuropeptides of animal origin in the treatment of neurological diseases. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2023;123(9):37-42. (In Russ.). https://doi.org/10.17116/jnevro202312309137
  36. Tyurenkov IN, Kurkin DV, Kalatanova AV, et al. Comparative study of protective effects of Cortexin, Cerebrolysin and Actovegin on memory impairment, cerebral circulation and morphological changes in the hippocampus of rats with chronic brain ischemia. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2020;120(8):83-89. (In Russ.). https://doi.org/10.17116/jnevro202012008183
  37. Putilina MV. Neuroprotective therapy of chronic cerebral ischemia. Doctor. 2008;8:27-32. (In Russ.).
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.